Target Ovarian Cancer regularly produces reports which cover issues including awareness of the symptoms of ovarian cancer and women’s experience of treatment.
Time is running out: the need for early diagnosis in ovarian cancer
Our new report outlines the delays that women with ovarian cancer can face in getting a diagnosis. The report highlights four areas where UK governments must act now to ensure that every woman is diagnosed as early as possible. We want to see; an end to the postcode lottery, ovarian cancer symptoms awareness campaigns, every GP trained on ovarian cancer and a shorter diagnostic pathway.
This is Target Ovarian Cancer’s second data briefing; we have analysed new government data on the stage at which women are diagnosed with ovarian cancer and how this varies across the country. The Prime Minister has set a target that 75 per cent of all cancers should be diagnosed at stage I or II by 2028. This briefing looks at the current picture for ovarian cancer and what needs to change.
Please note, the briefing does include survival data and statistics that some people may find upsetting. Everyone’s experience of ovarian cancer is different and it’s not possible to draw conclusions about your own diagnosis and treatment from these kind of figures. If you are recently diagnosed with ovarian cancer or are struggling to cope with your diagnosis, we encourage you to speak to your doctor about your personal prognosis rather than make assumptions based on UK-wide figures.
The following briefing appendix provides information on the percentage of women diagnosed with stage I or II ovarian cancer for every Clinical Commissioning Group (CCG) in England.
Target Ovarian Cancer has analysed new government data on ovarian cancer which includes routes to diagnosis, different types of tumour and treatment. This information helps measure the impact of work such as our GP education programme and identify areas where more needs to be done, for example, investing in research into less common types of ovarian cancer or campaigning for improved access to treatment.
The first report from the All-Party Parliamentary Group (APPG) on Ovarian Cancer shares the findings of its inquiry into early diagnosis. Alongside written evidence submissions, two oral evidence sessions heard from expert witnesses including Professor Chris Harrison, National Clinical Director for Cancer, NHS England, and Professor Anne Mackie, Director of Screening, Public Health England. The report calls for more to be done to raise awareness of the symptoms of ovarian cancer and for full roll-out of the cancer strategy as it relates to ovarian cancer.
Pathfinder England is our first report focusing exclusively on England. It looks at awareness of the symptoms of ovarian cancer, GP knowledge of the disease and women's experience of diagnosis and treatment.
Pathfinder Northern Ireland is our first report focusing exclusively on Northern Ireland. It looks at awareness of the symptoms of ovarian cancer, GP knowledge of the disease and women's experience of diagnosis and treatment.
Pathfinder Wales/Pathfinder Cymru is our first report focusing exclusively on Wales. It looks at awareness of the symptoms of ovarian cancer, GP knowledge of the disease and women's experience of diagnosis and treatment.
Pathfinder Scotland is our first report focusing exclusively on Scotland. It looks at awareness of the symptoms of ovarian cancer, GP knowledge of the disease and women's experience of diagnosis and treatment.
The first report from our GP Advisory Board looks at differences in the numbers of CA125 blood tests ordered, the time taken to complete non-obstetric ultrasounds, stage at diagnosis and one year survival rates for different parts of England. It calls for work to shorten the diagnostic pathway and improvements in how data is collected and used so all parts of the country can match the best performing areas.
Pathfinder is Target Ovarian Cancer’s groundbreaking research that provides a detailed picture of the experiences of people living and working with ovarian cancer in the UK. Pathfinder 2016 is our third UK wide report and is based on surveys of women in the general population, GPs, women with ovarian cancer, Clinical Nurse Specialists and family and friends. It shows where progress has been made but also where more remains to be done. It makes a series of recommendations including investment in national public awareness campaigns to ensure more women know the symptoms to look out for and a clinical audit to map diagnosis and treatment of ovarian cancer and identify areas for improvement.
While cancer doesn’t discriminate according to postcode, Target Ovarian Cancer research has found that women’s awareness of the symptoms, access to clinical trials and likelihood of surviving ovarian cancer can vary hugely according to where they live.
Pathfinder is Target Ovarian Cancer’s groundbreaking research that provides a detailed picture of the experiences of people living and working with ovarian cancer in the UK. Our second Pathfinder report highlighted delays in diagnosis, issues accessing Clinical Nurse Specialists and a fall in the number of women with ovarian cancer being offered access to clinical trials. In response we invested in GP training, launched our award-winning Ovarian Cancer Clinical Trials Information Centre and successfully campaigned for government funded awareness pilots for ovarian cancer.
Pathfinder is Target Ovarian Cancer’s groundbreaking research that provides a detailed picture of the experiences of people living and working with ovarian cancer in the UK. Our first ever Pathfinder study demonstrated that many women face delays in getting a diagnosis and that GPs lacked direct access to diagnostic tests; this led to a government commitment to investment in ultrasound.